Treatment options for hormone-refractory prostate cancer;Therapieoptionen des hormonrefraktären prostatakarzinoms

Urologe - Ausgabe A

Volumn 44, Issue 11, 2005, Pages 1303-1314

  Heidenreich, A ^a   Ohlmann, C H ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Bisphosphonates; Chemotherapy; Docetaxel; Hormone refractory prostate cancer; Ibandronate; Mitoxantrone; Zoledronate

Indexed keywords

ALENDRONIC ACID; ANDROGEN; ANTHRACYCLINE; ANTIANDROGEN; BICALUTAMIDE; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ESTRADIOL; ESTRAMUSTINE PHOSPHATE; ESTROGEN; FLUTAMIDE; HORMONE; HYDROCORTISONE; IBANDRONIC ACID; KETOCONAZOLE; MITOMYCIN; MITOXANTRONE; OXALIPLATIN; PACLITAXEL; PAMIDRONIC ACID; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; SOMATOSTATIN DERIVATIVE; TAXANE DERIVATIVE; TESTOSTERONE; UNINDEXED DRUG; ZOLEDRONIC ACID;

ADVANCED CANCER; ALGORITHM; ARTICLE; BONE DISEASE; BONE PAIN; CANCER SURVIVAL; CHEMOTHERAPY; CLINICAL TRIAL; HORMONAL THERAPY; HORMONE REFRACTORY PROSTATE CANCER; HUMAN; METASTASIS; PAIN; PROSTATE CANCER; STATISTICAL SIGNIFICANCE;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DIPHOSPHONATES; HUMANS; MALE; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 28044448527     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00120-005-0928-z     Document Type: Article

References (81)

1. Parker SL, Tong T, Bolden S, Wingo PA (1996) Cancer statistics. CA Cancer J Clin 46: 5-27
2. Wingo PA, Landis S, Ries LAG (1997) An adjustment to the 1997 estimate for new prostate cancer. CA Cancer J Clin 47: 239-242
3. Scher H, Steinneck G, Kelly WK (1995) Hormone-refractory (D3) prostate cancer: refining the concept. Urology 46: 142-148
4. Vogelzang NJ, Crawford ED, Zietman A (1998) Current clinical trial design issues in hormone-refractory prostate cancer. Cancer 82: 2093-2101
5. Tannock IF, Osoba D, Stockler MR et al. (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14: 1756-1764
6. Kanthoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, Trump D, Winer EP, Vogelzang NJ (1999) Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol 17: 2506-2513
7. Eisenberger MA, Abrams JS (1988) Chemotherapy for prostatic carcinoma. Semin Urol 6: 303-310
8. Yagoda A, Petrylak D (1993) Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 71 [Suppl 3]: 1098-1111
9. Heidenreich A, Schrader AJ (2003) The treatment of hormone refractory prostate cancer. EUA Update Series 1: 40-50
10. Eisenberger MA, de Wit R, Berry W et al. (2004) A multicenter phase III trial of docetaxel (D) + prednisone (P) and mitoxantrone (MTZ) + P in patients with hormone-refactory prostate cancer. Proc ASCO 23: 2(4)
11. Petrylak DP, Tangen C, Hussain M et al. (2004) SWOG 99-16: randomized phase III trial of docetaxel(D)/estramustine (E) vs. mitoxantrone(M)/ prednisone(P) in men with androgen-independent prostate cancer (AIPCA). Proc ASCO 23: 2(3)
12. Bubley GJ, Carducci M, Dahut W et al. (1999) Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the prostate-specific antigen working group. J Clin Oncol 17: 3461-3467
13. Manni A, Bartholomew M, Caplan R et al. (1988) Androgen priming and chemotherapy in advanced prostate cancer: evaluation of determinants of clinical outcome. J Clin Oncol 6: 1456-1466
14. Hussain M, Wolf M, Marshall E, Crawford ED, Eisenberger M (1994) Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: A southwest oncology group report. J Clin Oncol 12: 1868-1875
15. Taylor CD, Elson P, Trump DL (1993) Importance of testicular suppression in hormone-refractory prostate cancer. J Clin Oncol 11: 2167-2172
16. Fowler JE, Pandey P, Seaver LE et al. (1995) Prostate specific antigen after gonadal withdrawal and deferred flutamide treatment. J Urol 154: 448
17. Kelly WK, Scher HI (1993) Prostate specific antigen decline after antiandrogen withdrawal syndrome. J Urol 149: 607-609
18. Small EJ, Carroll PR (1994) Prostate-specific antigen decline after Casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. Urology 43: 408-410
19. Dawson NA, McLeod DG (1995) Dramatic prostate specific antigen decline in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome. J Urol 153: 1946-1947
20. Kojima S, Suzuki H, Akakura K, Shimbo M, Ichikawa T, Ito H (2004) Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy. J Urol 171: 679-683
21. Benson R, Hartley-Asp B (1990) Mechanisms of action and clinical uses of estramustine. Cancer Invest 8: 375
22. Seidman AD, Scher HI, Petrylak D et al. (1992) Estramustine and vinblastine: use of prostate specific antigen as a clinical trial and point for hormone refractory prostatic cancer. J Urol 147: 931-934
23. Hudes G, Einhorn L, Ross E et al. (1999) Vinblastine vs. vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: a Hoosier Oncology Group and Fox Chase Network phase III trial. J Clin Oncol 17: 3160-3166
24. Smith DC, Redman BG, Flaherty LE (1998) A phase II trial of oral diethylbestrol as a second line hormonal agent in advanced prostate cancer. Urology 52: 257-260
25. Klotz L, McNeill I, Fleshner N (1999) A phase 1-2 trial of diethylbestrol plus low-dose warfarin in advanced prostate carcinoma. J Urol 161: 169-172
26. Ockrim JL, Lalani EN, Laniado ME et al. (2003) Transdermal estradiol therapy for advanced prostate cancer - forward to the past? J Urol 169: 1735-1737
27. Ockrim H, Lalani-al N, Kakkar AD, Abel PD (2005) Transdermal estradiol therapy for prostate cancer reduces thrombophilic activation and protects against thromboembolism. J Urol 174: 527-533
28. Rochlitz CF, Damon LE, Russi MB et al. (1988) Cytotoxicity of ketoconazole in malignant cell lines. Cancer Chemother Pharmacol 21: 319-322
29. Small EJ, Baron AD, Fippin L (1997) Ketoconazole retains significant activity in patients with advanced prostate cancer who have progressed despite flutamide withdrawal. J Urol 159: 1204
30. Small EJ, Halabi S, Dawson NA et al. (2004) Antiandrogen withdrawal alone or in combination woth ketoconazole in androgen-dependent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 22: 1025-1033
31. Wilkinson S, Chodak G (2004) An evaluation of intermediate-dose ketoconazole in hormone refractory prostate cancer. Eur Urol 45: 581-584
32. Cordia I, Ohlmann CH, Özgür E, Engelmann UH, Heidenreich A (2005) Ketoconazole/hydrocortisone vs. estramustinphosphate in the management of PSA progression following primary androgendeprivation for metastatic prostate cancer. J Clin Oncol 23 [Suppl]: 419
33. Smith MR, Kabbinavar F, Saad F et al. (2005) Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 23: 2918-2925
34. Berry W, Dakhil S, Modiano M, Gregurich M, Asmar L (2002) Phase III study of mitoxantrone plus low dose prednisone vs. low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol 168: 2439-2443
35. Scotte F, Banu E, Oudard S et al. (2005) Prostate specific antigen doubling time (PSADT) before onset of chemotherapy as survival predictor for hormone refractory prostate cancer. J Clin Oncol 23 [Suppl]: 390
36. Semeniuk RC, Venner PM, Hanson J, North SA (2005) A retrospective review of prostate specific antigen doubling time (PSADT) in men with hormone refractory prostate cancer. J Clin Oncol 23 [Suppl]: 419
37. Dawson NA (1998) Apples and Oranges: Building a consensus for standardized eligibility criteria and end points in prostate cancer clinical trials. J Clin Oncol 16: 3398-3405
38. Strum SB, McDermed JE, Scholz MC, Johnson H, Tisman G (1997) Aneamia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol 9: 933-941
39. Bland LB, Tangen CM, Thompson IM et al. (2004) Prognostic value of anemia in untreated metastatic prostate cancer: a mukltivariate analysis of SWOG 8894. Proc ASCO 23: 399(4574)
40. Smith DC, Dunn RL, Strawderman MS, Pienta KJ (1998) Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J Clin Oncol 16: 1835-1843
41. Small EJ, McMillan A, Meyer M et al. (2001) Serum prostate antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer: association with progression free survival, pain end points and survival. J Clin Oncol 9: 1304
42. Verbel DA, Heller G, Kelly WK, Scher HI (2002) Quantifying the amount of variation in survival explained by Prostate-specific antigen. Clin Cancer Res 8: 2576-2579
43. Roessner M, de Wit R, Tannock IF et al. (2005) Prostate specific antigen (PSA) response as a surrogate endpoint for overall survival (OS): Analysis of the TAX 327 Study comparing docetaxel plus prednisone with mitoxantrone plus prednisone in advanced prostate cancer. J Clin Oncol 23 [Suppl]: 391
44. Heidenreich A, Sommer F, Ohlmann CH, Schrader AJ, Olbert P, Goecke J, Engelmann UH (2004) A prospective randomized phase II trial of pegylated doxorubicin (Caelyx™) in the management of symptomatic hormone refractory prostate cancer. Cancer 101: 948-956
45. Osoba D, Tannock IF, Ernst DS, Neville AJ (1999) Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol 17: 1654-1663
46. Trovedi C, Redman B, Flaherty LE et al. (2000) Weekly 1-hour infusion of paclitaxel. Clinical feasibility and efficacy in patients with hormone refractory prostate carcinoma. Cancer 89(2): 431-436
47. Kelly WK, Curley T, Slovin S et al. (2001) Paclitaxel, estramustin phosphate and carboplatin in patients with advanced prostate cancer. J Clin ONcol 19: 44-53
48. Smith DC, Esper P, Strawderman M, Redman B, Pienta KJ (1999) Phase II trial of oral estramustine, oral etoposide and intravenous paclitaxel in hormone-refractory prostate cancer. J Clin Oncol 17: 1664-1671
49. Urakami S, Igawa M, Kikuno N, Yoshino T, Kishi H, Shigeno K, Shi H (2002) Combination chemotherapy with paclitaxel, estramustine and carboplatin for hormone refractory prostate cancer. J Urol 168: 2444-2450
50. Schultz M, Wei J, Picus J et al. (1999) A phase II Trial of docetaxcel in Patients with homone refractory prostate cancer (HRPC). Proc Am Soc Clin Oncol 18: 355
51. Friedland D, Cohen J, Miller R et al. (1999) A phase II trial of Taxotere® in hormone refractory prostate cancer: Correlation of antitumor activity to phosphorylation of bcl-2. Proc Am Soc Clin Oncol 35: 1237
52. Picus J, Schultz M (1999) A phase II Trial of docetaxel in Patients with hormone refractory prostate cancer (HRPC): Long term results. Proc Am Soc Oncol 35: 1206
53. Picus J, Schultz M (1999) Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results. Semin Oncol 26: 14-18
54. Friedland D, Cohen J, Miller R Jr et al. (1999) A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2. Semin Oncol 26: 19-23
55. Berry W, Dakhil S, Gregurich MA and Asmar L (2001) Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. Semin Oncol 28: 8-15
56. Beer TM, Pierce W, Lowe BA, Henner WD (2000) Phase II study of weekly docetaxel (Taxotere) in hormone refractory metastatic prostate cancer (HRPC). ASCO, 2000
57. Gravis G, Bladou F, Salem N, Viens P (2001) Efficacy, quality of life (QoL) and tolerance with weekly docetaxel in metastatic hormone refractory prostate cancer: ASCO 2001
58. Oudard S, Banu E, Banu A et al. (2005) Docetaxel vs. mitoxantrone as first-line chemotherapy for hormone-refractory prostate cancer (HRPC) patients. A meta-analysis of 3 year overall survival results. J Clin Oncol 2 [Suppl] 3: 411
59. Heidenreich A, Carl S, Gleissner S, Moormann O (2003) Docetaxel and mitoxantrone in the management of hormone-refractory prostate cancer. Proc ASCO 22: 1655
60. Dahut WL, Gulley JL, Arlen PM et al. (2004) Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 22: 2532-2539
61. Berrutti A, Dogliotti L, Bitossi R et al. (2000) Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. J Urol 164: 1248-1253
62. Oefelein MG, Richuiti V, Conrad W, Seftel A, Bodner D, Goldman H, Resnick M (2001) Skeletal fracture rate associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. J Urol 166: 1724-1728
63. Smith MR (2002) Osteoporosis and other adverse body composition changes during androgen deprivation therapy for prostate cancer. Cancer Metastasis Rev 21: 159-166
64. Diamond TH, Winters J, Smith A, de Souza P, Kersley JH, Lynch WJ, Bryant C (2001) The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade. Cancer 92: 1444-1450
65. Smith MR, McGovern FJ, Zietman AL et al. (2001). Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 345: 989-991
66. Smith MR, Eastham J, Gleason DM, Shasa D, Tchekmedyian S, Zinner N (2003) Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 169: 2008-2012
67. Dearnaley DP, Sydes MR, on behalf of the MRC PRO5 collaboration (2001) Preliminary evidence that oral clodronate delays symptomatic progression of bone metastases from prostate cancer: first results of the MRC pro5 trial. Proc Am Soc Clin Oncol 20: 174
68. Ernst DS, Tannock IF, Venner PM et al. (2002) Randomized placebo-controlled trial of mitoxantron/prednisone and clodronate vs. mitoxantron/prednisone alone in patients with hormone-refractory. prostate cancer (HRPC) and pain: National Cancer Institute of Canada Clinical Trials Group study. Proc ASCO 21: 177
69. Saad F, Gleason DM, Murray R et al. (2002) A randomised, placebo-controlled trial of zoledronic acid in patients with hormone refractory metastatic prostate carcinoma. J Natl Cancer Inst 94: 1458-1468
70. Saad F, Gleason DM, Murray R et al. (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96: 879-882
71. Dawson NA (2002) Bisphosphonates: their evolving role in the management of prostate cancer-related bone disease. Curr Opin Urol 12: 413-418
72. Heidenreich A (2003) Bisphosphonates in the management of metastatic prostate cancer. Oncology 65 [Suppl 1]: 5-11
73. Heidenreich A, Hofmann R, Engelmann UH (2001) The use of bisphosphonates for the palliative treatment of painful osseous metastasis due to hormone refractory prostate cancer. J Urol 165: 136-140
74. Piga A, Bracci R, Ferretti B et al. (1998) A double blind randomized study of oral clodronate in the treatment of bone metastases from tumors poorly responsive to chemotherapy. J Exp Clin Cancer Res 17: 213-217
75. Strang P, Nilsson S, Brandstedt S et al. (1997) The analgesic efficacy of clodronate. Compared with placebo in patients with painful bone metastases from prostatic carcinoma. Anticancer Res 17: 4717-4721
76. Coleman RE, Ourohit OP, Vinholes JJ, Zekri J (1997) High-dose pamidronate: clinical and biochemical effects in metastatic bone disease. Cancer 80 [Suppl]: 1652-1660
77. Lipton A, Glover D, Harvey H, Grabelsky S, Zelenakas K, Macerata K, Seaman J (1994) Pamidronate in the treatment of bone metastases: results of 2 dose ranging trials in patients with breast and prostate cancer. Ann Oncol 5 [Suppl]: 31-35
78. Heidenreich A, Elert A, Hofmann R (2002) Ibandronate in the treatment of prostate cancer associated painful osseous metastases. Prostate Cancer Prostatic Dis 5: 231-235
79. Heidenreich A, Ohlmann C, Body JJ (2004) Ibandronate in metastatic bone pain. Sem Oncol 31: 67-72
80. Carducci MA, Padley RJ, Breul J et al. (2003) Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase-II placebo controlled trial. J Clin Oncol 21: 679-689
81. Vogelzang NJ, Nelson JB, Schulman CC et al. (2005) Meta-analysis of clinical trials of atrasentan 10 mg in metastatic hormone-refractory prostate cancer. J Clin Oncol 23 [Suppl]: 393